These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 19081408

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
    Gallo R, Steinhubl SR, White HD, Montalescot G, STEEPLE Investigators.
    Catheter Cardiovasc Interv; 2009 Feb 15; 73(3):319-25. PubMed ID: 19213086
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ, Califf RM.
    Am Heart J; 2006 Dec 15; 152(6):1042-50. PubMed ID: 17161049
    [Abstract] [Full Text] [Related]

  • 4. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR, STEEPLE Investigators.
    N Engl J Med; 2006 Sep 07; 355(10):1006-17. PubMed ID: 16957147
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, ESSENCE and TIMI 11B Investigators.
    Am Heart J; 2003 Jul 07; 146(1):33-41. PubMed ID: 12851605
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, Peters RJ, Budaj A, Afzal R, Chrolavicius S, Fox KA, Yusuf S.
    J Am Coll Cardiol; 2007 Oct 30; 50(18):1742-51. PubMed ID: 17964037
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S, ASPIRE Investigators.
    Circulation; 2005 Mar 22; 111(11):1390-7. PubMed ID: 15781750
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA, ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group.
    Circulation; 2004 Mar 02; 109(8):997-1003. PubMed ID: 14967716
    [Abstract] [Full Text] [Related]

  • 14. Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents.
    Li YJ, Rha SW, Chen KY, Poddar KL, Jin Z, Minami Y, Wang L, Dang Q, Li GP, Ramasamy S, Park JY, Choi CU, Kim JW, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Park JS, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim HS, Kim CJ, Yoon JH, Ahn TH, Tahk SJ, Chung WS, Seung KB, Park SJ, other Korea Acute Myocardial infarction Registry Investigators.
    Am Heart J; 2010 Apr 02; 159(4):684-690.e1. PubMed ID: 20362730
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, López-Sendón J, Laufenberg CV, Klutman M, Gowda N, Gulba D, GRACE Investigators.
    Eur Heart J; 2005 Nov 02; 26(21):2285-93. PubMed ID: 15932908
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL, Chen J, Qiao SB, Guo YL, Wu YJ, Dai J, Yuan JQ, Qin XW, Yang YJ, Gao RL.
    Chin Med J (Engl); 2006 Mar 05; 119(5):355-9. PubMed ID: 16542576
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
    Rao SV, Melloni C, Myles-Dimauro S, Broderick S, Kosinski AS, Kleiman NS, Dzavík V, Tanguay JF, Chandna H, Gammon R, Rivera E, Alexander JH, Fier I, Roach J, Becker RC, EMINENCE Investigators.
    Circulation; 2010 Apr 20; 121(15):1713-21. PubMed ID: 20368520
    [Abstract] [Full Text] [Related]

  • 20. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, Goodman SG, Dabbous OH, Agnelli G, GRACE Investigators.
    Am Heart J; 2007 Jun 20; 153(6):960-9. PubMed ID: 17540196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.